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Summary Antibody targeting has potential for selective delivery of cancer therapy. However, there is a wide
variation in the degree of antibody localisation in individual patients with colorectal adenocarcinoma.
Colorectal adenocarcinomas are composed of glandular structures separated from fibrovascular stroma by a
basal lamina which may represent a significant barrier to extravasated antibody. Basement membrane-
associated CEA epitopes may be more accessible to antibodies than those which are cytoplasmic or lumenal.
We have investigated, by immunohistochemistry and in vivo localisation, the extent to which distribution of
antigen epitopes influences targeting. Two monoclonal antibodies (A5B7 and EA77) recognising non-
overlapping CEA epitopes were reacted immunohistochemically with samples of 39 tumours. Intensity and site
of reaction were assessed for basement membrane, cytoplasmic or lumenal surface association. '251-labelled
antibodies were injected into nude mice bearing LS174T tumour. Per cent injected activity per gram was
measured in tumour and normal tissues, 24, 72 and 168 h later. Tissues reacted immunohistochemically for
CEA were autoradiographed to assess the relationship of injected antibody to target antigen. Immunohis-
tochemistry showed that A5B7 antibody favours basement membrane aspects of malignant glands; in contrast,
EA77 concentrated generally on lumenal surfaces. In vivo localisation showed that per cent inj.act g- in
tumour for A5B7 reached 36.5% at 24 h. EA77 localised to a lesser extent (9.1% at 24h), despite a longer
circulatory half-life. Autoradiography combined with immunohistochemistry showed A5B7 reacting with
antigen close to vasculature after 24 h, slowly penetrating deeper parts of the tumour by 72 h. In contrast,
EA77 was confined mainly to fibrovascular stroma, showing little labelling of antigen-positive tumour cells.
Localisation differences between A5B7 and EA77 may partly be due to accessibility of epitopes on tumour
cells.
The administration of radiolabelled antibodies against
tumour antigens is of value in the management of colorectal
adenocarcinomas for both tumour localisation in diagnosis
using external scintigraphy (Begent, 1985) and treatment
using radioimmunoguided surgery (Blair et al., 1990). The
rationale of those techniques depends upon the selectivity of
antibody for the target antigen expressed at the tumour site.
However the success of antibody-targeted therapy depends
not only upon the specificity of targeting but also on the
ability to deliver tumoricidal amounts of therapy to the
whole tumour (Humm & Cobb, 1990). Although partial and
complete responses have been reported with antibodies
directed against lymphomas (Grossbard et al., 1992), reports
of responses in colorectal cancer patients are limited (Begent
el al., 1989). This has been attributed, in part, to the
heterogeneity of antigen distribution (Edwards, 1985) and is
illustrated by the wide variation between patients in amount
of antibody (per cent injected activity per kg) localising in
tumour. Attempts to investigate which parameters are re-
sponsible for this variation have implicated a number of
factors (Shockley et al., 1991). There is some evidence that
the cellular organisation in colonic adenocarcinomas may
influence the efficiency with which antibody penetrates and is
retained at the tumour site (Boxer et al., 1992) and that a
critically important factor is the inaccessibility of tumour
antigen sites (Pervez et al., 1988). Furthermore, Pervez et al.
(1989) demonstrated that two antibodies directed against
different antigens on colonic adenocarcinoma cells (one pres-
ent lumenally and the other basolaterally associated), have
different distributions in vivo. Colorectal adenocarcinomas
are composed of complex glandular structures separated
from fibrovascular stroma by a basal lamina. Although this
basal lamina can be thin, interrupted or almost absent
(Ghadhially, 1985), it may still represent a significant barrier
to extravasated antibody molecules (Poznansky & Juliano,
1984; Dvorak et al., 1991). Tight junctions separating apical
and basolateral surfaces (Farquhar & Palade, 1963) are
thought to play an important role in the maintenance of cell
polarity (Herzlinger & Ojakian, 1984), and desmosomal
intercellular junctions are present on lateral membranes. In
malignant epithelium both these structures may hinder pas-
sage of antibody molecules.
Ahnen et al. (1982), demonstrated the localisation of CEA
in normal intestine and colon cancer at the ultrastructural
level using polyclonal antibodies. The results showed the
association of CEA with basement membranes and baso-
lateral surfaces of malignant colonic epithelium in tumours,
in contrast to the apical distribution in normal colon, sugges-
ting that the polarity of surface membrane components is
disturbed in neoplasia. Antibodies which bind epitopes that
are preferentially expressed on the lumenal surfaces of malig-
nant acini or cytoplasmically may not be capable of reaching
their target in vivo. Antibodies which bind to the basal and
basolateral aspect of these glandular structures (Abassi, 1993)
may have an advantage since the target is readily accessible
to molecules diffusing through fibrovascular stroma after
extravasation from the blood vessels.
This paper reports differences in the immunohistochemical
distribution of two intact mouse monoclonal antibodies
directed against non-overlapping epitopes on CEA. We have
compared the relative efficiency of localisation (per cent
injected activity in tumour and tumour to normal tissue
ratios) of these antibodies, both as single agents and as a
mixture, in the human tumour xenograft model LS174T.
Their microdistribution has been studied autoradio-
graphically.
Materials and methods
Antibodies
A5B7 and EA77 (anti-CEA antibodies) were obtained from
the Cancer Research Campaign (CRC) Targeting Group,
University Department of Clinical Oncology, Royal Free
Hospital, London, UK. BA57 (Harwood et al., 1986) and
EA.77 (Nap et al., 1992) are mouse monoclonal anti-CEA
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IgG antibodies which react with non-overlapping epitopes on
CEA. A5B7 (group 4) and EA.77 (group 2) have been char-
acterised under the Gold classification, by Nap et al. (1992).
Antibody IDIO (obtained from the CRC Targeting Group) is
directed against fetal microvillous membrane antigen and has
been used clinically by Blair et al. (1990). B72.3 antibody to
TAG-72 antigen (Nuti et al., 1982) and an anti-colon car-
cinoma antigen antibody, A33 (Welt et al., 1990), were
obtained from Celltech. Control sections were processed
without the primary antibody and with substitution of the
primary antibody with mouse IgG.
Immunofluorescence
Studies were performed on samples of colonic adenocar-
cinoma and normal flanking tissue from ten patients (eight
primary colonic adenocarcinomas and two metastatic
adenocarcinomas). A case of squamous carcinoma from the
anal margin was used as a cohtrol. Tissues were taken fresh
from resection specimens and snap frozen in isopentane,
cooled in liquid nitrogen. Cryostat sections (6rim) were cut,
air dried and then fixed in cold acetone for 5 min.
Preliminary immunofluorescence studies were carried out
using intact anti-CEA antibodies A5B7 and EA.77. Sections
were reacted for 30 min with primary antibody (15tsg ml-')
and washed in Tris-buffered saline (pH 7.4). They were then
incubated for 30 min with FITC-labelled rabbit anti-mouse
immunoglobulins (Vector Laboratories) diluted in 10% nor-
mal human serum, washed as before and then mounted in
aqueous media (Vectashield). Sections were examined under
fluorescence using the Zeiss Axiophot microscope and photo-
graphed.
Immunohistochemistry
A subsequent, more detailed characterisation of antibody
binding was performed using an immunohistochemical study
in a series of 39 additional samples of primary colorectal
adenocarcinoma and five samples of non-neoplastic mucosa.
Samples were snap frozen as before and cryostat sections
prepared. An avidin-biotin-peroxidase technique was used
as previously described (Southall et al., 1990). Sections were
incubated with primary antibody at a concentration of
15 Lgml-'.
Assessment ofimmunohistochemical reactivity
Antibody reactivity was scored on an arbitrary scale of inten-
sity ranging from + weak, + + moderate to + + + intense.
Equivocal reactions were scored as ±. Immunohistochemical
reactivity was assessed by recording the intensity of reaction
on both the lumenal surface and basement membrane aspect
ofmalignant glands. Intensity of reaction of the cytoplasm of
the cells was noted (data not shown). For each antibody, at
both the basal and lumenal aspects, the number of cases
which showed + + + reactions were recorded. Similar data
was generated for + +, +, ± and negative reactions.
For each antibody preparation, the number of tumours in
which antibody binding showed a significant increase or
gradient of reactivity from the basement membrane aspect to
the lumenal surface was recorded. The number of cases
where the direction of polarisation of binding was in the
opposite direction - towards the basement membrane aspect
- was also recorded.
Statistical analysis
Using the scoring system of + to + + +, values were attri-
buted to the immunohistochemical reaction at the basement
membrane aspect and at the lumenal surface of glandular
structures, for each antibody. Negative or equivocal reactions
scored 0, + scored 1, + + scored 2 and + + + scored 3.
From these data we compared reactions at the basement
membrane and lumenal surface using a Mann-Whitney U-
test, in the 39 cases, to assess whether there was any
significant difference for each antibody. Differences in the
intensity of reaction between EA77 and A5B7, both at the
basement membrane aspect and at the lumenal surface, were
tested for significance using the same statistical test.
Antibody localisation
A human colon adenocarcinoma cell line LS174T (Tom et
al., 1976) was used to develop a xenograft model in female
nude (nu/nu) mice by subcutaneous cell inoculation into the
flank. Subsequent passaging was by continuous subcutaneous
implantation of 1 mm3 xenograft fragments. All mice used
were 2-3 months old, and weighed between 20 and 25 g at
the initiation of experiments. Nude mice (nu/nu) were
implanted with human colonic adenocarcinoma xenograft
LS174T (Pedley et al., 1991) and used 3 weeks after passag-
ing when the mean tumour volume was approximately 1 cm3.
Mice were injected i.v. with 10fg ofeither 251I-labelled A5B7,
EA.77 or a mixture of both. Antibodies were radiolabelled by
the chloramine-T method over ice, to a specific activity of
1 tLCi rLg-'. After radioiodination anti-CEA antibodies, A5B7
and EA77, bound CEA antigen on a solid-phase radio-
immunoassay. LS174T tumour is a moderately differentiated
adenocarcinoma which grows as sheets of malignant cells
within which numerous small acini are formed. In most
tumours there are central areas of necrosis. The viable
tumour is supported by fibrovascular stroma and there are
some larger vascular spaces containing red cells. The connec-
tive tissue fibrovascular stroma is of mouse origin.
Gamma counting ofradioactivity
Animals were sacrificed at 24, 72 and 168 h after injection
(four animals per time point) and samples of tumour, blood,
liver, lung, kidney, spleen, colon and muscle were taken.
Samples were weighed, dissolved in 2 ml of 7 M potassium
hydroxide and counted for gamma radioactivity in a gamma
counter (Pharmacia - Wizard). Percentage injected activity
per gram (per cent inj.act g-1) of tissue was calculated as a
mean of the values in four mice (Pedley et al., 1987). Adja-
cent pieces of tissue were fixed in 10% formalin and pro-
cessed for routine histology. Tumour to blood ratios were
calculated.
Differences in tumour to blood ratio between EA77 and
A5B7 antibodies, and between A5B7 and the mixture of
antibodies (A5B7 + EA77), at each time point, were tested
for statistical significance using the Mann-Whitney U-test.
Autoradiography
Five-micron sections of tumour and normal tissues were cut,
mounted on glass slides pretreated with a 2% solution of 3,
amino-triethoxysilane and air dried overnight at 37°C. After
dewaxing in Inhibisol they were taken through graded
alcohols to distilled water and covered with autoradiographic
film. Briefly, in a darkroom slides were dipped for 8 s in a
nuclear emulsion (K5, Ilford), diluted 1:1 in 2% glycerol
(preheated to 42°C). They were air dried for 1 h and then
placed in a darkbox with silica gel and left overnight. Slides
were then transferred to lightproof darkboxes containing
silica gel and exposed at 4°C for 4 weeks. Serial sections were
first reacted immunohistochemically with A5B7 and EA.77
antibodies to CEA and then covered with autoradiographic
emulsion. Autoradiographs were developed as previously de-
scribed (Pedley et al., 1990) and counterstained with
haematoxylin and eosin. Immunohistochemically stained sec-
tions were counterstained with haematoxylin only.
Results
Immunofluorescence
In normal colonic mucosa, both A5B7 and EA.77 antibodies
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upper third of the colonic crypt. Some CEA reactivity was
observed at the lumenal surfaces of the middle and lower
parts of the crypt, but the intensity of binding was weaker
than that observed in the upper part of the crypt.
Immunofluorescence binding of anti-CEA antibodies A5B7
and EA.77 in the ten primary colorectal adenocarcinomas
showed three different distributions. These were (a) strong
lumenal staining, (b) strong basal staining and (c) strong
cytoplasmic reactions. The last was only observed in poorly
differentiated tumours. The intensity of binding was variable.
The binding of EA.77 was predominantly, and in some cases
exclusively, confined to the lumenal surface of glandular
acini, while A5B7 reacted primarily at the basement mem-
brane aspect of glands. Figure la (EA.77) and b and c
(A5B7) are representative photomicrographs illustrating the
different distributions associated with the two anti-CEA
antibodies in sections of colonic adenocarcinoma.
b
c
Figure 1 Photomicrographs of immunofluorescence binding of
anti-CEA antibodies in cyrostat sections of colonic adenocar-
cinoma: a, with EA77, showing lumenal surface reactivity of
malignant glands (x 120) and b and c with A5B7 demonstrating
b, basement membrane (x 120) and c, Lumenal surface reactivity
(x 60). LS, lumenal surface; BM, basement membrane.
Immunohistochemistry
Immunohistochemical reactivity in sections of non-neoplastic
colonic mucosa demonstrated differences in distribution of
antibody binding. Antibody binding could be categorised
into two groups. EA.77 (anti-CEA), B72.3 and lDIO all
showed strong reactions at the lumenal aspect of surface
epithelium and with lumenal surfaces of goblet cells lining
the crypts, cytoplasmic reactivity was weak. Figure 2a shows
the reaction of anti-CEA antibody EA.77. A5B7 (anti-CEA)
and A33 showed similar reactions but in addition bound
strongly to basal and basolateral cell membranes throughout
the crypt epithelium. Figure 2b (A5B7) and c (A33) show the
additional reactions of antibody with basal aspects of the
crypt epithelium. Cytoplasmic reactions were stronger,
especially with A33, which also showed strong reactions with
the basal surface epithelium. All of the 39 tumours studied
a
b
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Figure 2 Photomicrographs showing immunohistochemical reac-
tivity of a, EA77, b, A5B7 and c, A33 antibodies with normal
colonic mucosa (x 130).310 G.M. BOXER et al.
contained areas of moderately or well-differentiated tumour
with malignant glandular acini. Table I shows the intensity of
immunohistochemical binding in each tumour, for each anti-
body, at the basement membrane aspect and at the lumenal
surface of malignant glandular epithelium. There were signi-
ficant differences in intensity of binding of different anti-
bodies. In all but three tumours A5B7 reacted moderately
(+ +) or intensely (+ + +) with both the basal aspects and
lumenal surfaces of the malignant glands and there was no
significant difference in reaction at each site (P = 0.83) - an
example is shown in Figure 3a. EA.77 was more hetero-
geneous in its reactivity at the basal aspect, being moderately
or intensely reactive in only 17/39 tumours, with weak or
negative binding in the remainder (Figure 3b). In 38/39
tumours there was moderate or intense positivity with
lumenal surfaces. There was a significant difference between
the reaction of EA77 at the lumenal surface and that at the
basement membrane aspect (P = 0.001). Significant
heterogeneous reactions similar to those seen with EA.77
were exhibited by B72.3 (P = 0.001) (Figure 3c) and lDO0
(P = 0.001) antibodies (Figure 3d), 11/39 and 24/39 tumours
respectively showing moderate to intense reactivity at the
basal aspect. In contrast, A33 showed a more uniform dist-
ribution of reaction, similar to that of A5B7, anti-CEA, with
all tumours except one moderately or intensely positive in
their basal aspects (Figure 3e). There was no significant
difference between the reaction at basal or lumenal aspects
(P = 0.71). These data showing differences in immunohis-
tochemical binding imply that antibody reactivity with malig-
nant glandular structures can be significantly polarised across
the epithelium. Table II shows the direction of polarisation
of reactivity for each antibody in the 39 tumours. The
number of tumours with significant polarisation of binding
towards the lumenal surface was much higher for EA.77 than
for A5B7. The values for the other intact antibodies screened
were also recorded. B72.3 and lDIO, like EA.77, showed
many tumours with polarisation towards the lumenal surface.
The polarisation of A33 was similar to A5B7 with only a few
tumours showing a preference for antibody binding at the
lumenal aspect.
The number of tumours in which polarisation was towards
the basement membrane aspect was more limited, A5B7, and
to lesser extent A33, showing this trend in a few cases only.
In none of the 39 tumours did EA77, B72.3 or IDIO show
any polarisation of reactivity towards the basal aspect. Statis-
tical analysis shows that the binding of EA77 and A5B7 at
the basal aspect of the glands was significantly different
(P = 0.001), but there was no difference in antibody reaction
at the lumenal surface (P = 0.28). These results show that the
polarisation of binding of EA.77 was in the direction of the
lumenal surface. In many cases binding to basal and
basolateral margins was either absent or only very weak.
Table I Immunohistochemical distribution of antibodies in
colorectal adenocarcinomas
Number of cases positive
Antibody Neg + + + + + + +
EA77 (anti-CEA)
Basal aspect 3 2 17 8 9
Lumenal 0 0 1 8 30
ASB7 (anti-CEA)
Basal aspect 0 0 3 11 25
Lumenal 0 0 3 10 26
B72.3
Basal aspect 11 1 16 8 3
Lumenal 2 0 5 9 23
A33
Basal aspect 0 0 1 7 31
Lumenal 0 0 3 6 30
IDJO
Basal aspect 2 0 13 18 6
Lumenal I 1 2 12 23
There were only three tumours in which ASB7 showed
polarisation of binding towards the basement membrane.
This was because lumenal surfaces were also reactive in the
other 36 cases, so there was homogeneous reactivity through-
out malignant glandular epithelium and this is reflected in the
lack of significance using the Mann-Whitney U-test. How-
ever, in all but three cases there was moderate or intense
reactivity at the basal aspect. Similar observations were made
in the analysis of A33 binding (only one tumour showing
polarisation to basal aspect).
Of the antibodies studied, A33 antibody and A5B7 anti-
CEA showed the strongest binding with tumour cell cyto-
plasm. However, in all but two tumours (for A33) or in all
tumours (for A5B7), reactions were always equivalent or
weaker than those observed at the basal aspect and
lumenally. In contrast, B72.3 antibody, lDIO antibody and
EA77 anti-CEA antibody all showed cytoplasmic reactions
which varied in intensity from tumour to tumour. However,
for B72.3 and EA77, in all 39 cases the intensity of cytoplas-
mic reactions was always equivalent or stronger than that
observed at the basal aspect.
Xenograft localisation
Figure 4 shows the biodistribution of anti-CEA antibodies,
A5B7 and EA.77, in the nude mouse xenograft model at (a)
24 h, (b) 72 h and (c) 168 h after injection. A5B7 gave con-
sistently higher concentrations in the tumour than EA77 in
spite of being cleared more rapidly from the blood and
therefore being less available for tumour binding. The mean
tumour to blood ratios for EA.77 at 24, 72 and 168 h after
injection were 0.36:1, 0.43:1 and 0.76:1 respectively. A5B7
ratios were higher at 3.2:1, 4.97:1 and 9:1. At each time
point, analysis of the tumour to blood ratios for individual
mice showed that they were significantly increased for A5B7
at 24 h (P = 0.02) and at 168 h (P = 0.02). The tumour to
blood ratios were also higher for A5B7 at 72 h. These results
demonstrate the superior localisation of A5B7 antibody com-
pared with EA.77 in terms of hoth absolute dose to tumour
and tumour to blood ratio.
The per cent inj.act g' measured in the tumour for the
mixture at the three time points was 18.3%, 14.88% and
7.31%, with corresponding levels in the bloodstream of
14.4%, 9.6% and 5.09%. Combining A5B7 and EA.77
antibodies decreased the activity in tumour compared with
A5B7 alone and by prolonging the half-life ofradioactivity in
the bloodstream the tumour to blood ratios at 24, 72 and
168 h (1.27: 1, 1.55:1, and 1.43:1 respectively) were
significantly decreased (P = <0.05).
Autoradiography
Sections of LS174T, from animals receiving 125I-labelled
antibody, were reacted immunohistochemically with A5B7
and EA.77 prior to autoradiography, to show the relation-
ship between the site of target epitope and injected
radiolabelled antibody. A5B7 immunohistochemistry showed
that reactivity in the human tumour xenograft was confined
mainly to the surfaces close to vascular spaces and blood
vessels with some binding to cytoplasm of tumour cells and
to a much lesser extent at the lumenal surfaces of small
glandular acini. At 24 h after injection of A5B7 antibody,
accumulations of grains indicative of bound radiolabelled
antibody were strongly associated with areas of antigen
positivity close to blood vessels and vascular spaces and
could also be seen at less dense concentrations in adjacent
cells (Figure 5a). Further away from vascular spaces there
were very few grains. By 72 h there were still grains
associated with areas of antigen but antibody could be
detected further from blood vessels in underlying tumour
cells. By 168 h overall grain density was reduced, consistent
with the lower per cent inj.act g1' measured in tumour,
although there was still evidence of localisation in cells away
from vessels. By comparison, few grains were observed over-
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Figure 3 High-power photomicrographs showing immunohistochemical reactivity of a, A5B7, b, EA77, c, B72.3, d, IDIO and e,
A33 antibodies with serial sections from an adenocarcinoma of the colon (x 260). In a, with A5B7 and e, with A33, note the
brown reaction product at the basement membrane aspect of the malignant gland. LS, lumenal surface; BM, basement mem- brane.
sections prestained with EA77, even in regions which were
reactive immunohistochemically. The immunohistochemical
reactivity of EA.77 was heterogeneous and mainly confined
to the cytoplasm of tumour cells and small glandular acini
and is shown in Figure 5b. Only occasional reactivity could
be demonstrated at the basal aspect of the tumour associated
with the interface between the fibrovascular stroma and the
tumour cells. Where EA.77 antigen epitope was demonstrable
adjacent to vessels there were accumulations in grains, but
this was rare and there was little evidence of any labelling of
deeper tumour cells at 24, 72 or 168 h after injection.
Autoradiographs from mice that received radiolabelled EA77
demonstrated, at the 24 h and 72 h (Figure 5c) time points,
that most grains were overlying vascular spaces and in some
areas were associated with red cells or areas of haemorrhage.
Grains were also evident in the fibrous stromal compartment.
By 168 h there was little or no labelling of grains in sections.
Serial autoradiograph sections which had not been pretreated
immunohistochemically were counterstained with haematoxy-
lin and eosin. These showed similar grain distributions to
those seen in sections that had been reacted with antibody
prior to autoradiography and confirmed the results reported
above.
Discussion
This paper demonstrates that the immunohistochemical dist-
ribution of A5B7 antibody is strongly associated with the
basement membrane aspect of malignant glands within
adenocarcinomas of the colon and rectum. The reactivity of
EA.77 in general is concentrated on the lumenal surface of
the acini. These polarised distributions, while not mutually
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Table II Direction of polarisation across glandular epithelium from
immunohistochemical reactivity of antibodies to colorectal
adenocarcinoma
Antibody
EA.77 (intact)
A5B7 (intact)
B72.3
A33
IDIO
0
0-
E
a) 0
a) 0
0
0
0a
'a)
Direction of polarisation of reactivity
Towards Towards
lumenal surface basement membrane
27/39 0/39
4/39 3/39
25/39 0/39
1/39 1/39
18/39 0/39
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exclusive, show a consistent trend over the majority of car-
cinoma samples investigated as well as in the non-neoplastic
samples of colonic mucosa. CEA on the basement membrane
aspect of malignant glandular structures may represent a
more accessible target for antibodies administered into the
circulation than that present cytoplasmically or on lumenal
surfaces. Intense immunohistochemical reactivity at the
lumenal surface of normal colonic epithelium by antibodies
to CEA is not mirrored in localisation studies in patients.
Tumour to normal bowel ratios are invariably higher than
some other tumour to organ ratios in organs in which
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Figure 4 The biodistribution of anti-CEA antibodies, A5B7 (0)
and EA.77 (A), in the nude mouse xenograft model LS174T, in
tumour, normal tissues and blood at a, 24 h, b, 72 h and c, 168 h
after injection.
Figure 5 Photomicrographs from autoradiographs showing the
microdistribution of anti-CEA antibodies A5B7 and EA77 in
sections of colonic adenocarcinoma xenograft LS174T (x 130). a,
A section prestained immunohistochemically with A5B7 showing
radiolabelled antibody (black grains) close to vascular spaces,
24 h after injection. VS, vascular space. b, Poor localisation of
EA77 antibody, 24 h after injection, with few grains (autoradio-
graph prestained immunohistochemically with EA77). L, lumen;
C, cytoplasm; FB, fibrovascular stroma. c, Accumulations of
grains in an area of fibrovascular stroma, 72 h after injection of
EA77 antibody (section prestained with EA77). V, blood vessel;
S, stroma.
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antigen is not expressed (Boxer et al., 1992). Also, the micro-
distribution of radiolabelled antibodies to CEA in patients
suggests that antibodies do not always penetrate malignant
glands, with isolated cells often targeted, while there is
heterogeneous or no uptake by more complex epithelial
structures (Boxer et al., 1992).
The relatively superior localisation of A5B7 antibody com-
pared with EA.77 and many other antibodies to colorectal
tumour antigens may in part be due to the location and
accessibility of the antigen on tumour cells in vivo. Whether
A5B7 binds to basement membrane aspects of malignant
glands solely because of presence of antigen or whether there
are additional factors influencing binding is unclear.
Recently, Yokota et al. (1992) compared the relative
efficiency of localisation of genetically engineered antibody
fragments (Fab' and scFv of CC-49) with their intact
relatives in the LS174T tumour model and have found
different penetration rates, the scFv molecules having the
fastest rate but also the lowest percentage injected activity in
the tumour. However, the absolute depth of penetration into
tumour xenografts was similar for all antibody types if
enough time was allowed. This suggests that there is a limit
to the penetration of these molecules in tumours. Such
molecules are too large even as Fab' (50,000 Da) and scFv
(27,000 Da) fragments to pass through intact cellular junc-
tions which will exclude molecules above a molecular weight
of 2,000 Da (Jain, 1989). Kyriakos et al. (1992) have demon-
strated that binding to the surface of viable tumour cells by
intact antibody is irreversible and suggest that the concept of
affinity may not be applicable. They have postulated that
intact immunoglobulin bound to the surface of tumour cells
may be gradually internalised as a result of non-clathrin-
dependent endocytosis during the normal turnover of cell-
surface molecules.
Our autoradiographic results show that A5B7 localises to
antigen which is accessible to extravasated antibody and can
be shown to penetrate to more distant cells. These may have
been reached and targeted via internalisation. In contrast,
EA.77 antibody is observed in the vascular spaces and
fibrovascular stroma, yet is either not present or only
detected at low levels in association with malignant tissues.
Whether this is simply because of the absence of the CEA
epitope recognised by EA.77 on the basal aspect of tumour
cells or whether there are physical barriers associated with
basement membrane structures is unclear. Several groups
have shown that significant amounts of radiolabelled
antibody accumulate in necrotic areas of tumour (Steis et al.,
1990). Where glandular structures have necrosed the basal
and basolateral epithelial membranes will be breached, thus
facilitating the diffusion of antibody to tumour cells and
CEA antigen which would otherwise be inaccessible.
In this study immunohistochemical reactivity of antibodies
lDIO and B72.3, like that of EA.77, has been shown to be
polarised towards the lumenal surface aspect of malignant
glands. The relative success of these antibodies in the clinic
has been limited compared with that of A5B7 (Blair et al.,
1990; D.M. Lane et al., in preparation). In contrast, A33
antibody, which shows strong reactions at the basal aspect of
malignant glandular epithelium, is well localised in patients
(Welt et al., 1990) and gives similar tumour uptake to A5B7
in the human tumour xenograft LS174T (R.B. Pedley, per-
sonal observation).
In the LS174T xenograft A5B7 immunohistochemistry
shows strong reactivity at the basal surface of tumour cells
adjacent to the fibrovasculature. In addition, there is cyto-
plasmic reactivity with some tumour cells and lumenal sur-
faces of some acini. In contrast, EA77 reacts heterogeneously
with little evidence of binding to CEA epitopes at the basal
aspect of the tumour masses and much of the immunohisto-
chemical reactivity is cytoplasmic and lumenal. While the
histological structure of the LS174T xenograft does not
exactly model that of most colorectal ad-enocarcinomas in
patients, it is sufficiently differentiated to demonstrate
epithelial polarisation. Differences in epitope distribution
recognised by A5B7 and EA77 are shown by immunohis-
tochemistry in both the tumour specimens and the xenograft
model. These differences may, but do not necessarily, account
for the difference in in vivo localisation. The question of
whether EA77 has a lower binding affinity for its epitope
than A5B7 has for its own epitope has yet to be answered.
Evidence from antibody affinity column chromatography
demonstrates differences in epitope specificity between EA77
and A5B7. A5B7 reacts with an epitope on all or most CEA
molecules, whereas EA77 binds to an epitope available on
only a minority of molecules. It has been shown that EA77
binds with greater affinity to EA.77-purified CEA than to
A5B7-purified CEA (P. Keep, personal communication).
Whatever the reasons for the poor localisation of EA.77 in
this human tumour xenograft, these experiments highlight the
need to investigate critically the reactivity of antibodies
immunohistochemically. EA.77 has been shown to be highly
specific for CEA with no cross-reactions, and A5B7 has some
cross-reactivity with NCA (non-specific cross-reacting
antigen). These studies demonstrate that highly selective
antibodies with better specificity need not be superior
targeting agents.
Our observations suggest that the immunohistochemical
distribution of antibodies against colorectal tumour antigens
may give an indication of their potential for efficient localisa-
tion in patients.
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